Search - tctmd.com

Displaying 481 - 500 of 671

Sort: Relevancy | Date

News Daily News

Bivalirudin Shows Advantage Over GPIs—But Not Heparin Alone—in STEMI Patients

L.A. McKeown

November 28, 2012

News Daily News

Study Shows Impact of Public Health Communication on Clopidogrel Use Post DES

November 20, 2012

News Daily News

Estudio muestra el impacto de la comunicación de salud pública en el uso de clopidogrel después de la colocación de un SLF

November 20, 2012

Presentation

Evaluating the Impact of Public Health Notification: Duke Clopidogrel Experience

Presenter: Eric L. Eisenstein

November 19, 2012

Presentation

Discontinuation of Long-term Clopidogrel Therapy Is Associated with Death and MI After SVG PCI

Presenter: A. Sachdeva

November 13, 2012

News Daily News

Risk Peaks Early After Clopidogrel Cessation in SVG PCI Patients

November 13, 2012

News Conference News AHA 2012

No Mortality Benefit with Prolonged Dual Antiplatelet Therapy

November 05, 2012

Presentation TCT 2012

Debate: Clopidogrel is Enough and Still Plays a Role for Most!

Presenter: Michael Love

October 25, 2012

Presentation TCT 2012

ADAPT-DES One Year: A Large-Scale, Multicenter, Prospective, Observational Study of the Impact of Clopidogrel and Aspirin Hyporesponsiveness on Patient Outcomes

Presenter: Gregg Stone

October 25, 2012

Presentation TCT 2012

Clopidogrel Is Still the Choice for Most!

Presenter: Shamir Mehta

October 24, 2012

Presentation TCT 2012

TCT-54. The Influence of Smoking Status on the Pharmacodynamics of Prasugrel and Clopidogrel: The PARADOX Study

Presenter: Paul Gurbel

October 23, 2012

Presentation TCT 2012

TCT-51. Comparison of Clopidogrel and Prasugrel in Patients with Unprotected Left main Disease Treated with Everolimus-eluting Stents: Insight from the Florence Left Main-PCI...

Presenter: Renato Valenti

October 23, 2012

Presentation TCT 2012

TCT-49. A Comparison of 5 mg Prasugrel with 75 mg Clopidogrel in Very Elderly Coronary Artery Disease Patients: Pharmacodynamics and Rates of High on-Treatment Reactivity

Presenter: Joseph Jakubowski

October 23, 2012

Presentation TCT 2012

TCT-55. Major Adverse Cardiac Events Associated with Discontinuation of Clopidogrel Treatment Within the First Year After Coronary Stent Implantation in Western Denmark

Presenter: Michael Maeng

October 23, 2012

Presentation TCT 2012

PARADOX: A Prospective, Randomized Trial of Clopidogrel and Prasugrel in Smokers and Non-Smokers

Presenter: Paul Gurbel

October 22, 2012

Presentation TCT 2012

A Prospective, Randomized Trial of Tailored Clopidogrel Therapy vs. Prasugrel in Patients with High On-Treatment Platelet Reactivity

Presenter: Laurent Bonello

October 22, 2012

News Daily News

La Bivalirudina Reduce las Hemorragias en Pacientes NSTEMI sometidos a PCI

Jason Kahn

October 19, 2012

News Daily News

Bivalirudin Lowers Bleeding in NSTEMI Patients Undergoing PCI

Jason Kahn

October 19, 2012

Presentation

Bivalirudin vs. Heparin Plus a GPI in Pts with NSTEMI Undergoing PCI After Clopidogrel Pretreatment

Presenter: G. Ndrepepa

October 18, 2012

News Daily News

Un Estudio Avala ½ Dosis de Prasugrel en Pacientes de Poco Peso con EAC

October 18, 2012

Advertisement

Bivalirudin Shows Advantage Over GPIs—But Not Heparin Alone—in STEMI Patients

Study Shows Impact of Public Health Communication on Clopidogrel Use Post DES

Estudio muestra el impacto de la comunicación de salud pública en el uso de clopidogrel después de la colocación de un SLF

Evaluating the Impact of Public Health Notification: Duke Clopidogrel Experience

Discontinuation of Long-term Clopidogrel Therapy Is Associated with Death and MI After SVG PCI

Risk Peaks Early After Clopidogrel Cessation in SVG PCI Patients

No Mortality Benefit with Prolonged Dual Antiplatelet Therapy

Debate: Clopidogrel is Enough and Still Plays a Role for Most!

ADAPT-DES One Year: A Large-Scale, Multicenter, Prospective, Observational Study of the Impact of Clopidogrel and Aspirin Hyporesponsiveness on Patient Outcomes

Clopidogrel Is Still the Choice for Most!

TCT-54. The Influence of Smoking Status on the Pharmacodynamics of Prasugrel and Clopidogrel: The PARADOX Study

TCT-51. Comparison of Clopidogrel and Prasugrel in Patients with Unprotected Left main Disease Treated with Everolimus-eluting Stents: Insight from the Florence Left Main-PCI...

TCT-49. A Comparison of 5 mg Prasugrel with 75 mg Clopidogrel in Very Elderly Coronary Artery Disease Patients: Pharmacodynamics and Rates of High on-Treatment Reactivity

TCT-55. Major Adverse Cardiac Events Associated with Discontinuation of Clopidogrel Treatment Within the First Year After Coronary Stent Implantation in Western Denmark

PARADOX: A Prospective, Randomized Trial of Clopidogrel and Prasugrel in Smokers and Non-Smokers

A Prospective, Randomized Trial of Tailored Clopidogrel Therapy vs. Prasugrel in Patients with High On-Treatment Platelet Reactivity

La Bivalirudina Reduce las Hemorragias en Pacientes NSTEMI sometidos a PCI

Bivalirudin Lowers Bleeding in NSTEMI Patients Undergoing PCI

Bivalirudin vs. Heparin Plus a GPI in Pts with NSTEMI Undergoing PCI After Clopidogrel Pretreatment

Un Estudio Avala ½ Dosis de Prasugrel en Pacientes de Poco Peso con EAC

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content